Illumina, Inc. (ILMN) Given Average Rating of “Hold” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given a consensus rating of “Hold” by the twenty-four brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $175.02.

A number of analysts recently weighed in on ILMN shares. Bank of America Corporation upped their target price on shares of Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 price target for the company. in a report on Tuesday, April 11th. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $187.00 price target (up from $170.00) on shares of Illumina in a report on Friday, April 14th. Finally, Cantor Fitzgerald upped their price target on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th.

ILLEGAL ACTIVITY WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/analysts-set-illumina-inc-ilmn-target-price-at-162-30-updated-updated/1198925.html.

Illumina (NASDAQ:ILMN) opened at 197.61 on Tuesday. Illumina has a 52-week low of $119.37 and a 52-week high of $199.86. The firm has a 50 day moving average of $176.74 and a 200-day moving average of $172.43. The stock has a market cap of $28.85 billion, a PE ratio of 39.65 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. During the same period in the prior year, the firm earned $0.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts anticipate that Illumina will post $3.65 earnings per share for the current fiscal year.

In related news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $180.24, for a total transaction of $3,604,800.00. Following the completion of the sale, the director now owns 539,176 shares in the company, valued at approximately $97,181,082.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of Illumina stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $175.53, for a total value of $2,632,950.00. Following the sale, the director now owns 534,176 shares of the company’s stock, valued at approximately $93,763,913.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 132,339 shares of company stock valued at $23,619,735. Company insiders own 1.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Forte Capital LLC ADV boosted its stake in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares in the last quarter. Chevy Chase Trust Holdings Inc. boosted its stake in Illumina by 33.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 346,451 shares of the life sciences company’s stock worth $59,114,000 after buying an additional 85,922 shares in the last quarter. Private Asset Management Inc. boosted its stake in Illumina by 10.5% in the first quarter. Private Asset Management Inc. now owns 8,142 shares of the life sciences company’s stock worth $1,389,000 after buying an additional 775 shares in the last quarter. Philadelphia Trust Co. boosted its stake in Illumina by 0.8% in the fourth quarter. Philadelphia Trust Co. now owns 13,027 shares of the life sciences company’s stock worth $1,668,000 after buying an additional 100 shares in the last quarter. Finally, Opus Point Partners Management LLC boosted its stake in Illumina by 3.1% in the fourth quarter. Opus Point Partners Management LLC now owns 18,967 shares of the life sciences company’s stock worth $2,429,000 after buying an additional 567 shares in the last quarter. Hedge funds and other institutional investors own 93.81% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.